LDL, HDL and endocrine-related cancer

Cholesterol is essential for a variety of functions in endocrine-related cells, including hormone and steroid production. We have reviewed the progress to date in research on the role of the main cholesterol-containing lipoproteins; low-density lipoprotein (LDL) and high-density lipoprotein (HDL), a...

Descripción completa

Detalles Bibliográficos
Autores: Revilla, Giovanna|||0000-0003-2971-5651, Cedó, Lídia|||0000-0003-4354-3411, Tondo Colomer, Mireia|||0000-0002-0301-9984, Moral, Antonio|||0000-0001-5551-0145, Pérez, José Ignacio, Corcoy i Pla, Rosa|||0000-0001-5055-6814, Lerma Puertas, Enrique|||0000-0001-7908-2747, Fuste, Victoria|||0000-0001-5065-3737, Reddy, Srivinasa T., Blanco Vaca, Francisco|||0000-0001-7380-5385, Mato, Eugènia|||0000-0001-8121-9335, Escolà-Gil, Joan Carles|||0000-0001-9021-2485
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:271452
Acceso en línea:https://ddd.uab.cat/record/271452
https://dx.doi.org/urn:doi:10.1016/j.semcancer.2020.11.012
Access Level:acceso abierto
Palabra clave:Cancer
Cholesterol
Endocrine
HDL
LDL
Descripción
Sumario:Cholesterol is essential for a variety of functions in endocrine-related cells, including hormone and steroid production. We have reviewed the progress to date in research on the role of the main cholesterol-containing lipoproteins; low-density lipoprotein (LDL) and high-density lipoprotein (HDL), and their impact on intracellular cholesterol homeostasis and carcinogenic pathways in endocrine-related cancers. Neither LDL-cholesterol (LDL-C) nor HDL-cholesterol (HDL-C) was consistently associated with endocrine-related cancer risk. However, preclinical studies showed that LDL receptor plays a critical role in endocrine-related tumor cells, mainly by enhancing circulating LDL-C uptake and modulating tumorigenic signaling pathways. Although scavenger receptor type BI-mediated uptake of HDL could enhance cell proliferation in breast, prostate, and ovarian cancer, these effects may be counteracted by the antioxidant and anti-inflammatory properties of HDL. Moreover, 27-hydroxycholesterol a metabolite of cholesterol promotes tumorigenic processes in breast and epithelial thyroid cancer. Furthermore, statins have been reported to reduce the incidence of breast, prostate, pancreatic, and ovarian cancer in large clinical trials, in part because of their ability to lower cholesterol synthesis. Overall, cholesterol homeostasis deregulation in endocrine-related cancers offers new therapeutic opportunities, but more mechanistic studies are needed to translate the preclinical findings into clinical therapies.

Similares en LA Referencia